Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	3.81B
Revenue (ttm)	270.93M
Net Income (ttm)	-801.29M
Shares Out	92.14M
EPS (ttm)	-8.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,118
Average Volume	37,512
Open	41.35
Previous Close	41.20
Day's Range	41.20 - 41.50
52-Week Range	37.05 - 54.90
Beta	0.72
RSI	63.12
Earnings Date	Mar 6, 2025

About Medeon Biodesign

Medeon Biodesign, Inc. researches, develops, manufactures, and sells medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site hernia...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2023, Medeon Biodesign's revenue was 196.26 million, a decrease of -34.21% compared to the previous year's 298.32 million. Losses were -1.20 billion, 177.7% more than in 2022.